The Thalidomide Tragedy was the result of marketing and greed for profit over the well-being of patients. Developed in 1957 by Chemie Grünenthal, little or no testing was done on the drug before it was happily prescribed to pregnant women. After an abnormal increase of the rise of rare birth defects, the efficacy was questioned. The final estimates of damage rendered can hardly be measured. Tens of thousands of babies dies, over ten thousand were born with irreparable nerve and organ damage. Most common of the defects were the malformed legs and arms of the child. In 1968, the company, with it's army of legal representation, pressured a paltry settlement with the families affected. The battle for compensation continues now in over 40 countries. The drug remains in use in Latin America as a treatment for leprosy.